| LLY |
Eli Lilly and Company |
95%
|
ervice institutions, non-profit clinics, and Federal government entities purchasing via the Federal Supply Schedule, purchase directly from our wholesalers. Contracted customers generally purchase th… |
| LLY |
Eli Lilly and Company |
95%
|
Reciprocal relationship from LLY graph: Reciprocal relationship from INCY graph: ervice institutions, non-profit clinics, and Federal government entities purchasing via the Federal Supply Schedule, p… |
| MGNX |
MacroGenics, Inc. |
90%
|
Reciprocal relationship from MGNX graph: Reciprocal relationship from INCY graph: Reciprocal relationship from MGNX graph: Reciprocal relationship from INCY graph: Reciprocal relationship from MGNX g… |
| NVSEF |
Novartis AG |
72%
|
Reciprocal relationship from NVSEF graph: Reciprocal relationship from INCY graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from INCY graph: Reciprocal relationship from NVSE… |
| NVSEF |
Novartis AG |
72%
|
(in thousands): December 31, 2024 2023 Raw materials $ 27,590 $ 23,282 API and Work-in-process 331,178 209,793 Finished goods 48,431 36,862 Total inventory $ 407,199 $ 269,937 Inventories, stated at … |
| ORANY |
ORANY |
72%
|
Reciprocal relationship from ORANY graph: Reciprocal relationship from INCY graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from INCY graph: pabilities may be disproportional… |
| ORANY |
ORANY |
72%
|
pabilities may be disproportional compared to the revenues we may be able to generate on sales of our products. We are continuing to establish and maintain sales, marketing and distribution capabilit… |
| AGENUS-SWITZERLAND-INC |
AGENUS-SWITZERLAND-INC |
62%
|
(in thousands): December 31, 2024 2023 Raw materials $ 27,590 $ 23,282 API and Work-in-process 331,178 209,793 Finished goods 48,431 36,862 Total inventory $ 407,199 $ 269,937 Inventories, stated at … |
| ANTIBODY-AG |
ANTIBODY-AG |
62%
|
(in thousands): December 31, 2024 2023 Raw materials $ 27,590 $ 23,282 API and Work-in-process 331,178 209,793 Finished goods 48,431 36,862 Total inventory $ 407,199 $ 269,937 Inventories, stated at … |
| ARIAD-PHARMACEUTICALS-INC |
ARIAD-PHARMACEUTICALS-INC |
62%
|
esting. Compensation expense for PSUs with market performance conditions is calculated using a Monte Carlo simulation model as of the date of grant and recorded over the requisite service period. Adv… |
| CHIEF-HUMAN-RESOURCES |
CHIEF-HUMAN-RESOURCES |
62%
|
applicable regulatory requirements, we could incur significant delays in our clinical trials or interruption of commercial supply which could have a material adverse effect on our business. We have e… |
| CHINA-MEDICAL-SYSTEM-HOLDINGS-LIMITED |
CHINA-MEDICAL-SYSTEM-HOLDINGS-LIMITED |
62%
|
ent of operations. Research and development expenses for the period from January 1, 2024 to the asset acquisition on February 5, 2024, includes $ 10.7 million, related to our 55 % share of the co-dev… |
| CHINA-MEDICAL-SYSTEMS-HOLDINGS-LIMITED |
CHINA-MEDICAL-SYSTEMS-HOLDINGS-LIMITED |
62%
|
ent of operations. Research and development expenses for the period from January 1, 2024 to the asset acquisition on February 5, 2024, includes $ 10.7 million, related to our 55 % share of the co-dev… |
| ESCIENT-PHARMACEUTICS-INC |
ESCIENT-PHARMACEUTICS-INC |
62%
|
ange in the accruals from prior periods, and assessed the historical accuracy of management’s estimates against actual results. We also tested the completeness and accuracy of the underlying data use… |
| INNOVENT-BIOLOGICS-INC |
INNOVENT-BIOLOGICS-INC |
62%
|
ervice institutions, non-profit clinics, and Federal government entities purchasing via the Federal Supply Schedule, purchase directly from our wholesalers. Contracted customers generally purchase th… |
| PADAGIS-ISRAEL-PHARMACEUTICALS-LTD |
PADAGIS-ISRAEL-PHARMACEUTICALS-LTD |
62%
|
rate on sales of our products. We are continuing to establish and maintain sales, marketing and distribution capabilities for OPZELURA. Successful commercialization of our drug candidates for dermato… |
| SUN-PHARMACEUTICAL-INDUSTRIES-INC |
SUN-PHARMACEUTICAL-INDUSTRIES-INC |
62%
|
rate on sales of our products. We are continuing to establish and maintain sales, marketing and distribution capabilities for OPZELURA. Successful commercialization of our drug candidates for dermato… |
| SUN-PHARMACEUTICAL-INDUSTRIES-LTD |
SUN-PHARMACEUTICAL-INDUSTRIES-LTD |
62%
|
rate on sales of our products. We are continuing to establish and maintain sales, marketing and distribution capabilities for OPZELURA. Successful commercialization of our drug candidates for dermato… |
| XENCOR-ESCIENT-PHARMACEUTICALS-INC |
XENCOR-ESCIENT-PHARMACEUTICALS-INC |
62%
|
. Moreover, we may terminate the Xencor collaboration agreement without cause upon 90 days’ advance written notice to Xencor. In the event that (i) we terminate this agreement for convenience or (ii)… |
